How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

805 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Metronidazole-Induced Bullous Pemphigoid: A Case Report Full Text available with Trip Pro

Metronidazole-Induced Bullous Pemphigoid: A Case Report Bullous pemphigoid is an autoimmune cutaneous blistering disorder, the exact pathogenesis of which is still not fully elucidated. Drug-induced bullous pemphigoid eruptions are rare but have been reported earlier with the use of frusemide, psoralens, ibuprofen, galantamine hydrobromide, ACE inhibitors like captopril, spironolactone, penicillin, ampicillin, levofloxacin, penicillamine. We hereby report a case of metronidazole induced bullous

2015 Journal of clinical and diagnostic research : JCDR

282. Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

(donepezil, rivastigmine or galantamine) dosing within 2 months prior to screening. Changes in memantine dosing within 2 months prior to the screening. Changes in antidepressant dosing or addition of another antidepressant medication within 2 months prior to the screening. Use of antipsychotics at any dose within 1 month prior to screening. Use of benzodiazepines, other than short-acting sleep medications, for night at a maximum of 3 nights/week, within 2 months prior to screening. Use of any

2015 Clinical Trials

283. Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

/clinically contraindicated as determined by investigator in order to comply with procedural testing of cognitive function as well as ensure study safety. See list of prohibited medications and compounds undergone a recent change (<1mo) in their prescribed acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) or memantine. undergone a recent change (<1mo) in their selective serotonin re-uptake inhibitor (SSRI) or anti-depressant medication current or recent drug or alcohol abuse

2015 Clinical Trials

284. Antidementia drug treatment in people screened positive for dementia in primary care. Full Text available with Trip Pro

, controlled intervention trial to implement and evaluate an innovative concept of collaborative dementia care management in Germany. Our sample consists of n = 243 subjects who screened positive for dementia.29.6% (n = 72) of participants received antidementia drugs: memantine 44.5% (n = 32); donepezil 30.5% (n = 22); rivastigmine 13.9% (n = 10); galantamine 11.1% (n = 8). A total of 46.4% (n = 45) of the subgroup of participants with a formal dementia diagnosis received antidementia drug treatment

2015 Journal of Alzheimer's disease : JAD Controlled trial quality: uncertain

285. Risk of pneumonia in new users of cholinesterase inhibitors for dementia. Full Text available with Trip Pro

Risk of pneumonia in new users of cholinesterase inhibitors for dementia. To compare the risk of pneumonia in older adults receiving donepezil, galantamine, or rivastigmine for dementia.Retrospective cohort study.Nationally representative 5% sample of Medicare databases.Medicare beneficiaries aged 65 and older who newly initiated cholinesterase inhibitor therapy between 2006 and 2009.Pneumonia, defined as the presence of a diagnosis code for pneumonia as the primary diagnosis on an inpatient (...) claim or on an emergency department claim followed by dispensing of appropriate antibiotics. Cox proportional hazards models were used to estimate the risk of pneumonia. Subgroup analyses and sensitivity analyses were conducted using alternative pneumonia definitions and adjustments using high-dimensional propensity scores to test the robustness of the results.The mean age of 35,570 new users of cholinesterase inhibitors (30,174 users of donepezil, 1,176 users of galantamine, 4,220 users

2015 Journal of the American Geriatrics Society

286. [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

confinement in small places and would be unable to undergo MRI or PET scanning Part 2 Only: - Has been administered an AChEI within the prior 3 months or will require administration of an AChEI during study Part 3 Only: Has been administered galantamine within the prior 7 days or will require administration of galantamine during study History within 2 years prior to screening, or current evidence of any neurological or neurodegenerative disorder other than AD that is associated with transient or sustained

2015 Clinical Trials

287. Cognitive Brain Training in Older Adults

-dementia medications (e.g., donepezil, galantamine, etc.) during the 8-week study period are able to walk independently; are suitable to engage in 15-minutes of brisk walking based on the Physical Activity Readiness Questionnaire; and provide a personally signed and dated informed consent document indicating that the individual has been informed of all pertinent aspects of the study. Exclusion Criteria: diagnosed with dementia of any type clinically suspected to have neurodegenerative disease

2015 Clinical Trials

288. Mirabegron in Parkinson Disease and Impaired Cognition

criteria for PD. At baseline visit (Visit 2) patients must have: At least 8 micturitions per 24 hours and At least 3 urgency episodes per 3-day diary. A MoCA score between 19 and 28 (inclusive) at screening. For those on cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29 (inclusive) at screening. Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical (...) , rivastigmine, memantine, galantamine), must be on stable dose at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study. EXCLUSION CRITERIA: Known or suspected alcohol or substance abuse in the preceding 12 months. Women who are pregnant or breastfeeding. Women of childbearing potential (WOCP) who are not using at least one method of contraception. Patients with severe renal impairment (CLcr ≤ 29 mL/min, or eGFR ≤ 29 mL/min/1.73 m2), or moderate or severe

2015 Clinical Trials

289. Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

cholinesterase inhibitors [eg, donepezil, galantamine, rivastigmine] should be on a stable dose for at least 3 months before Screening Patient has a negative drug screen (benzodiazepines or opiates) at Screening Female patients must have had last natural menstruation ≥ 24 months before Screening, OR be surgically sterile Male patients must agree to use of effective contraception if female partner is of childbearing potential, OR be surgically sterile Exclusion Criteria: Patient has an alternative cause

2015 Clinical Trials

290. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Full Text available with Trip Pro

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Treatment in moderate or severe Alzheimer's disease (AD) often involves adding memantine to a cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials and long-term observational studies supports superiority of memantine-ChEI combination to ChEI monotherapy. We

2015 Alzheimer's research & therapy Controlled trial quality: uncertain

291. Enzyme Inhibitory Properties, Antioxidant Activities, and Phytochemical Profile of Three Medicinal Plants from Turkey Full Text available with Trip Pro

to evaluate the antioxidant capabilities of the extracts. The half-maximal inhibitory concentrations (IC50) of the extracts on cholinesterase, tyrosinase, and α-amylase were significantly higher than the references, galantamine, kojic acid, and acarbose, respectively. The half-maximal effective concentrations (EC50) of the extracts on TAC, CUPRAC, and FRAP were significantly higher than trolox. The phenol and flavonoid contents of the plant extracts were in the range 20.90 ± 0.190-83.25 ± 0.914 mg gallic

2015 Advances in pharmacological sciences

292. A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression Full Text available with Trip Pro

) alleles aged 18-27 years were tested on four nonconsecutive nights. Participants were given galantamine (an anti-acetylcholinesterase), buspirone (a serotonergic agonist), both drugs together, or placebos before sleeping.As reported previously, buspirone significantly increased rapid eye movement (REM) latency (P<0.001), as well as awakenings, percentage of time spent awake, and percentage of time asleep spent in stage N1 (P<0.019). Galantamine increased awakenings, percentage of time spent awake (...) , percentage of time asleep spent in stage N1, and percentage of time asleep spent in REM, and decreased REM latency and percentage of time asleep spent in stage N3 (P<0.019). Galantamine plus buspirone given together disrupted sleep more than either drug alone, lowering sleep efficiency and percentage of time asleep spent in stage N3 and increasing awakenings, percentage of time spent awake, and percentage of time asleep spent in stage N1 (P<0.019). There was no main effect of genotype nor

2015 Nature and science of sleep

293. Domperidone for Chronic Nausea and Vomiting

, atomoxetine, chloral hydrate, chloroquine, ciprofloxacin, citalopram, clozapine, cocaine, dexmethylphenidate, diphenhydramine, dobutamine, dofetilide, dopamine, dronedarone, ephedrine, epinephrine, eribulin, escitalopram, famotidine, felbamate, fenfluramine, fingolimod, fosphenytoin, galantamine, gatifloxacin, gemifloxacin, granisetron, iloperidone, isoproterenol, lapatinib, levalbuterol, lisdexamfetamine, lithium, metaproterenol, methadone, methylphenidate, midodrine, moxifloxacin, nilotinib

2015 Clinical Trials

294. Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial. Full Text available with Trip Pro

) including donepezil, rivastigmine and galantamine.In a multicenter, nonblinded, randomized controlled trial, 264 volunteers with AD were randomly divided into 4 groups of 66; groups 1, 2, 3 and 4 received donepezil, rivastigmine, MLC601 and galantamine, respectively. Subjects underwent a clinical diagnostic interview and a cognitive/functional battery including the Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog). Patients were visited every 4

2015 Dementia and geriatric cognitive disorders extra Controlled trial quality: uncertain

295. Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors. Full Text available with Trip Pro

randomized controlled trials with donepezil, rivastigmine or galantamine compared to placebo in participants with Alzheimer's disease were included. Data from a nationwide cohort of persons with clinically verified diagnoses of Alzheimer's disease was defined as a reference population.128 full-text articles were assessed for eligibility, 31 of them fulfilled criteria. Mean age of participants in randomized controlled trials (n = 15,032) was 5.8 years lower (95% CI 5.7 to 5.9, P < 0.001), compared

2015 PloS one

296. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Full Text available with Trip Pro

effects of donepezil and rivastigmine for cognitive and psychiatric symptoms. Rivastigmine, but not donepezil, was associated with greater risk of adverse events. Meta-analysis of memantine suggested that it is well tolerated but with few benefits. Descriptive summaries provide some evidence of benefits for galantamine, modafinil, levodopa, rotigotine, clozapine, duloxetine, clonazepam, ramelteon, gabapentin, zonisamide, and yokukansan. Piracetam, amantadine, selegiline, olanzapine, quetiapine

2015 The American Journal of Psychiatry

297. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer’s disease Full Text available with Trip Pro

, rivastigmine, galantamine, and huperzine A for 24 weeks (n=22). At baseline, 12 weeks, and 24 weeks, the patients were evaluated using mini-mental state examination (MMSE) and Alzheimer Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scales. Adverse events were recorded to analyze the safety profile.The MMSE scores were significantly increased and the ADL scores were significantly decreased at 12 weeks and 24 weeks in all five groups compared with baseline (all P<0.01). At 24 weeks

2015 International journal of clinical and experimental medicine Controlled trial quality: uncertain

298. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Full Text available with Trip Pro

Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. The present study evaluated the differences in treatment outcomes and brain perfusion changes among 3 types of acetylcholinesterase inhibitors (AchEIs, i.e. donepezil, rivastigmine, and galantamine).This was a prospective, longitudinal, randomized, open-label, 3-arm (donepezil, rivastigmine (...) , or galantamine), parallel-group, 12-month clinical trial carried out in 55 patients with AD.At 6 months, the results of the Mini-Mental State Examination (MMSE) and the Trail Making Test (TMT)-Part A showed an improvement versus baseline in the donepezil treatment group. All groups showed a significant increase in regional cerebral blood flow (rCBF), mainly in the frontal lobe. Significant rCBF reduction was observed in the temporal lobe and cingulate gyrus in all 3 groups.AchEI treatment prevents

2015 Dementia and geriatric cognitive disorders extra Controlled trial quality: uncertain

299. Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use. Full Text available with Trip Pro

Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use. Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate antagonist (memantine) to reduce cognitive symptoms. However

2015 BMC health services research

300. Pharmacovigilance in Gerontopsychiatric Patients

: Citalopram Drug: Paroxetine Drug: Sertraline Drug: Fluvoxamine Drug: Escitalopram Drug: Tranylcypromine Drug: Moclobemide Drug: Mianserin Drug: Trazodone Drug: Mirtazapine Drug: Bupropion Drug: Venlafaxine Drug: Reboxetine Drug: Duloxetine Drug: Agomelatine Drug: Pyritinol Drug: Piracetam Drug: Donepezil Drug: Rivastigmine Drug: Galantamine Drug: Memantine Drug: Nicergoline Drug: Acamprosate Drug: Lithium Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical (...) : Reboxetine Drug: Duloxetine Drug: Agomelatine Drug: Pyritinol Drug: Piracetam Drug: Donepezil Drug: Rivastigmine Drug: Galantamine Drug: Memantine Drug: Nicergoline Drug: Acamprosate Drug: Lithium Outcome Measures Go to Primary Outcome Measures : Assessment of frequency and severity of adverse events [ Time Frame: Participants will be followed for the duration of hospital stay and the follow-up-visit, an expected average of 6 weeks ] Secondary Outcome Measures : Assessment of cognitive functioning [ Time

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>